Global Biocatalysis CDMO Services Market Strategic Research Report

Scope of the Report

The global Biocatalysis CDMO Services market size is predicted to grow from US$ 2,250 million in 2025 to US$ 3,434 million in 2032; it is expected to grow at a CAGR of 6.4% from 2026 to 2032.

Biocatalysis CDMO Services refer to contract development and manufacturing services that utilize enzymes, engineered microorganisms, or whole-cell biocatalysts to develop, optimize, scale up, and manufacture pharmaceutical intermediates, active pharmaceutical ingredients (APIs), fine chemicals, agrochemicals, food ingredients, and specialty chemicals through highly selective, environmentally sustainable, and cost-efficient biocatalytic processes.

The Biocatalysis CDMO Services industry chain begins with upstream suppliers of enzymes, microbial strains, genetic engineering tools, fermentation media, bioreactors, chromatography materials, analytical instruments, and laboratory consumables, continues through midstream contract research, enzyme engineering, strain optimization, process development, fermentation, purification, analytical testing, regulatory support, pilot production, technology transfer, and commercial manufacturing by specialized CDMOs, and extends downstream to pharmaceutical, biotechnology, fine chemical, agrochemical, food ingredient, cosmetic, and industrial biotechnology companies seeking cost-effective, sustainable, highly selective, and scalable manufacturing solutions for commercial products and innovative molecular development.

Projects under construction and planned in the Biocatalysis CDMO Services market include GMP biocatalysis manufacturing facilities, commercial-scale enzyme fermentation plants, microbial strain engineering centers, continuous bioprocessing production lines, high-throughput enzyme screening laboratories, pilot-scale biomanufacturing facilities, integrated CDMO campuses, digital bioprocess automation systems, biologics and small-molecule manufacturing expansions, and sustainable green chemistry production platforms across North America, Europe, and Asia-Pacific to address growing outsourcing demand from pharmaceutical, biotechnology, specialty chemical, food ingredient, and industrial biotechnology sectors requiring high-performance biocatalytic manufacturing capabilities.

2025 Global Market Average Gross Profit Margin: 36%.

Global key Biocatalysis CDMO Services players cover Cambrex, Ajinomoto Bio-Pharma Services, Sterling Pharma Solutions, Almac Sciences, Johnson Matthey, etc.

This report presents a comprehensive overview of the global Biocatalysis CDMO Services market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Biocatalyst Type

• Enzyme Catalysis
• Whole Cell Catalysis
• Immobilized Enzyme Catalysis
• Microbial Biocatalysis
• Others

Segment by Development Stage

• Research Services
• Preclinical Manufacturing
• Clinical Manufacturing
• Commercial Manufacturing
• Others

Segment by Application

• Food and Beverage
• Dietary Supplement
• Pharmaceutical
• Infant Formula
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Biocatalysis CDMO Services market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Food and Beverage, Dietary Supplement, Pharmaceutical evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact